Search

In medical research missing values often arise in the course of a data analysis. This fact constitutes a problem for different reasons, so e.g. standard methods for analyzing data lead to biased estimates and a loss of statistical power due to missing values, since those methods require complete data sets and therefore omit incomplete cases for the analyses. Furthermore missing values imply a certain loss of information for what reason the validity of results of a study with missing values has to be rated less than in a case where all data had been available. For years there are methods for replacement of missing values (Rubin, Schafer) to tackle these problems and solve them in parts. Hence in this article we want to present the existing software to handle and replace missing values on the one hand and give an outline about the available options to get information on the other hand. The methodological aspects of the replacement strategies are delineated just briefly in this article.

The specific treatment of primary breast carcinoma in the future may depend on viral genes in the development of antiviral substances, or a specific chemotherapeutic method. In this manner the turnover rate of the RNS virus is successfully inhibited (as the preceding communicated observations about the probably produced inhibition effect of rifampicin derivates of streptovarizin complexes). Prophylactically, by familiar breast cancer, breast feeding must be prohibited so that a supposed virus factor would not transfer with the milk. So far we hope that a supposed virus diagnosis of the primary tumor leads to decreased surgical interventions (tumorectomy, radical mastectomy), and technical as well as high energy postradiotherapy. This would not only give a smaller psychologic shock to the patient (small operation trauma) but would also decrease the complications (arm edema, movement restriction). This opinion now appears to effect international thinking after radical and subradical surgery have not given better results. For the late stage there is modern chemotherapy, combined with proper radiotherapy treatment of painful skeletal metastases, eventually also brain metastases which can now be successfully irradiated. Whether better late results are obtained by the early chemotherapy as well as the improvement of the immunity reaction quickly after sugical intervention (modified radical mastectomy) will be seen in the near future.

A short introduction deals with the frequency, the distribution and the histology of eyelid-tumors. Then the indication, the technics and the efficiency of X-ray therapy is discussed. Only malignomes of the early stage of TU I and TU II that are made sure by histological research may be treated by an experienced X-ray therapist. It is pointed to the importance of cooperation and the common planning between ophthalmic-surgical and X-ray therapeutics centers and the oculist. Observing the correct indication and technics we reached 97% of 5 years healing by X-ray therapy with our material of malign tumours of the eyelid in the early stage of TU I and TU II.